Company intelligence / Profile preview
CatalYm
Munich/Martinsried, Bavaria, Germanycatalym.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CatalYm’s lead antibody, visugromab, has shown durable anti-tumor efficacy and long-lasting objective responses in relapsed and refractory metastatic solid tumor patients when combined with anti-PD‑1 therapy. In the GDFATHER trial, an objective response rate of ~16.7% was observed across heavily pretreated patients with NSCLC, urothelial carcinoma, and HCC. The average duration of response exceeded 15 months for NSCLC; most responses are ongoing. Safety profile has been excellent to date.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Clinical collaboration with Bristol Myers Squibb for combination trials using Opdivo/nivolumab as anti-PD–1 backbone therapy
Beyond the preview
Go deeper on CatalYm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CatalYm.